Zacks Investment Research
30 Sept 2026, 15:50 UTC · 1h ago
Verdict
Headline takes no side. We score IART +0.60 across three claims — strongly bullish.
+0.60strongly bullish
More positive than 78% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish · 0 new · 3 priced in
Integra LifeSciences' Specialty Surgery revenues increased 1.6% organically to $309.3 million in the second quarter of 2026.
Priced inanalysis of Q2 results reported earlier
So whatWith organic growth at only 1.6%, the segment needs significant acceleration in H2 to drive a meaningful beat on FY2026 top-line estimates.
More positive than 55% of claims this week
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
Integra continues to face challenges from high leverage and currency fluctuations.
Priced ingeneral company challenges cited
So whatHigh leverage restricts the company's ability to fund the Braintree production ramp via debt, increasing the risk of future equity dilution.
More negative than 68% of claims this week
The company's earnings yield of 22.1% is significantly higher than the industry average of negative 0.9%.
Priced inanalysis of trailing data
So whatThis yield spread suggests the stock is trading at a steep discount to peers, potentially providing a floor for the multiple.
More positive than 46% of claims this week
Which stocks this story touches
More positive than 78% of ticker scores this week
Company sees steady demand in specialty surgery, improving operational efficiency, and holds a Zacks Rank #2 (Buy).
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
1h ago
−2.0%
Price is moving against the score
$16.31 vs $16.64 close before publication (Sep 29) · not market-adjusted
IART chart →
